Active	Status	Sponsor type	Region	Phase	Filter
2 Active 3 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Her-VAXX / Pevion, Imugene
nextHERIZON, NCT05311176: A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer	Terminated	2	7	RoW	IMU-131, HER-Vaxx, Ramucirumab plus Paclitaxel, Standard of Care Chemotherapy, Pembrolizumab, Keytruda	Imugene Limited	Gastric Cancer, Cancer of Stomach, Gastric Adenocarcinoma, Stomach Cancer, Stomach Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	04/24	04/24
HERIZON, NCT02795988: A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer	Completed	1/2	64	RoW	IMU-131, HER-Vaxx, Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine., Standard of Care Chemotherapy	Imugene Limited	Gastrointestinal Neoplasms, Adenocarcinoma	03/24	03/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Her-VAXX / Pevion, Imugene
nextHERIZON, NCT05311176: A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer	Terminated	2	7	RoW	IMU-131, HER-Vaxx, Ramucirumab plus Paclitaxel, Standard of Care Chemotherapy, Pembrolizumab, Keytruda	Imugene Limited	Gastric Cancer, Cancer of Stomach, Gastric Adenocarcinoma, Stomach Cancer, Stomach Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	04/24	04/24
HERIZON, NCT02795988: A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer	Completed	1/2	64	RoW	IMU-131, HER-Vaxx, Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine., Standard of Care Chemotherapy	Imugene Limited	Gastrointestinal Neoplasms, Adenocarcinoma	03/24	03/24